Sharon Benzeno - 11 Mar 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Reporting relationship: Chief Commercial Ofc Imm Med
Issuer ticker: ADPT
Reported as of: 11 Mar 2026
Net transaction value: -$831,067
SEC form: 4
Accepted by SEC: 13 Mar 2026, 20:55:04 UTC
Prior SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact

Key filing fact

Sharon Benzeno filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 13 Mar 2026.

Key facts

This page summarizes Sharon Benzeno's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Mar 2026, 20:55.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: -$831,067.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780854 Primary reporting owner

BENZENO SHARON

Relationship: Chief Commercial Ofc Imm Med
Address: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE
Signature: /s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact
Signature date: 13 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADPT transaction

Common Stock

Sale

Transaction value: $831,067
Shares: -63,103
Change %: -19%
Price: $13.17
Shares after: 272,751
Date: 11 Mar 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.